This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The State University of New York. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Matthew Gumbleton: Innovator in Natural Killer Cell Activation
Introduction
Matthew Gumbleton is a notable inventor based in Syracuse, NY (US). He has made significant contributions to the field of immunology, particularly in the activation of natural killer (NK) cells. His innovative work has the potential to impact the treatment of various diseases.
Latest Patents
Matthew Gumbleton holds a patent for "Ship inhibition to induce activation of natural killer cells." This invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in methods aimed at inhibiting SHIP to induce broad activation of NK cells. This advancement could lead to new therapeutic approaches for treating diseases.
Career Highlights
Matthew Gumbleton is affiliated with the State University of New York, where he continues to engage in research and development in his field. His work is characterized by a commitment to advancing scientific knowledge and improving health outcomes.
Collaborations
He collaborates with William Garrow Kerr, contributing to the innovative research environment at the university.
Conclusion
Matthew Gumbleton's contributions to the field of immunology through his patent and research efforts highlight his role as an influential inventor. His work in activating natural killer cells represents a promising avenue for future medical advancements.